Our Pledge

At Foghorn, we pledge to partner with patients as we work to discover and develop new, effective therapies for a wide spectrum of diseases, including many types of cancer. Every member of our team is committed to making a difference in the lives of our fellow human beings.

CLINICAL TRIAL

Clinical trials are studies that are conducted to evaluate the safety and effectiveness of a new therapy. These studies are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

PRIMARY TARGET POPULATION NON-SMALL CELL LUNG CANCER (NSCLC)

FHD-909 (LY4050784)

Evaluating the safety, tolerability and initial efficacy of FHD-909 in patients with locally advanced or metastatic solid tumors harboring a SMARCA4 alteration.
Status: RECRUITING

To learn more about this study, please visit ClinicalTrials.gov

POLICY ON EXPANDED ACCESS (EA) TO INVESTIGATIONAL DRUGS

Currently, participation in clinical trials is the only way for patients to gain access to Foghorn’s investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.

FDA Guidance on EA

Interested in active trials?

CLINICALTRIALS.GOV

To learn more about the above study, please visit ClinicalTrials.gov